Articles tagged "Rejection"

2021 American Transplant Congress
Outcomes of Cytomegalovirus Status Determining Induction Therapy in Lung Transplant
K. Heagler¹, J. Lyons¹, B. Bemiss², P. Stracener¹
¹Pharmacy, Loyola University Medical Center, Maywood, IL, ²Loyola University Medical Center, Maywood, IL
*Purpose: At the study institution, basiliximab induction is withheld in lung transplant recipients who are cytomegalovirus (CMV) high risk due to concern for increased CMV…
2021 American Transplant Congress
Guiding Therapeutic Plasma Exchange for Amr Treatment in Lung Transplant Recipients Using Serial Dilution in Single Antigen Bead Assay
O. A. Timofeeva¹, J. Choe², M. Alsammak², E. J. Yoon², S. Geier², K. Carney², J. Au², A. Diamond², J. A. Galli², K. Shenoy², A. Mamary², S. Seghal², P. Mullhal², Y. Toyoda², N. Shigemura², F. Cordova², G. Criner², J. Brown²
¹MedStar Georgetown University Hospital, Washington, DC, ²Temple University Hospital, Philadelphia, PA
*Purpose: Development of donor‐specific antibodies (DSA) is associated with poor outcomes in lung transplantation. Patients who are presented with at least probable AMR require treatment;…
2021 American Transplant Congress
Therapeutic Response of Late Clinical Cell Mediated Rejection is Modeled by Chronicity Changes
I. Melgarejo¹, V. Visnawathan², A. Sharma¹, P. Sood¹, C. Puttarajappa¹, C. Wu¹, N. Shah¹, M. Molinari¹, S. Hariharan¹, R. Mehta¹
¹Starzl Transplant Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Medicine, Renal-Electrolyte Division, University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Although there is a tendency to treat late clinical TCMR, the responsiveness to steroids is unclear.*Methods: Among kidney transplant recipients, transplanted between Jan 2013…
2021 American Transplant Congress
Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction
R. Hod Dvorai¹, R. Lee², P. Muluhngwi², M. Raijmakers³, A. Shetty², A. Tambur², M. Ison²
¹SUNY Upstate Medical University, Syracuse, NY, ²Northwestern University, Chicago, IL, ³University of Santiago, Santiago, Chile
*Purpose: To evaluate development of de novo donor specific antibodies (dnDSA) in Renal Transplant Recipients (RTR) with immunosuppression (IS) modulation due to BK viremia (BKV)…
2021 American Transplant Congress
DAP12 Promotes Liver DC Tolerogenicity by Negative Regulation of the CGAS-STING-IFN I Pathway
Y. Zheng¹, J. Long², N. Ryosuke¹, L. Peng³, F. Peng³, A. Thomson¹
¹Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, ²Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, China, ³Department of Kidney Transplantation, The Second Xiangya Hospital of Central South University, Changsha, China
*Purpose: Constitutive expression of comparatively high levels of DNAX-activating protein of 12KDa (DAP12) by liver myeloid dendritic cells (mDCs) has been implicated in their immune…
2021 American Transplant Congress
Real-time Donor-derived Cell-free Dna Kinetics Indicate Decreased “Molecular Injury” During Treatment of Acute Renal Allograft Rejection
R. Hinojosa¹, K. M. Hitchman², D. J. Ross³, R. C. Hall¹, J. E. Nelson¹, E. L. Kincaide¹, K. Klein¹, A. M. Bell³
¹Pharmacotherapy Education and Research Center | Long School of Medicine, UT Health San Antonio | University Transplant Center, University Health, San Antonio, TX, ²Long School of Medicine, UT Health San Antonio | University Transplant Center, University Health, San Antonio, TX, ³CareDx, Inc., Brisbane, CA
*Purpose: Dd-cfDNA is a validated plasma analyte (t½~30 min) for surveillance of renal transplant (KT) rejection with limited reports characterizing response to acute allograft rejection…
2021 American Transplant Congress
Outcomes of HLA Antibody Surveillance Protocol in Heart Transplant Patients – A Single-Center Retrospective Analysis
S. S. Patlolla, V. Bhattad, S. McKean, M. Askar, S. Hall
Baylor University Medical Center, Dallas, TX
*Purpose: Post-transplant care is multifaceted with protocols to provide oversight and maintain the standard of care. While institutional protocols for post-transplant HLA antibody surveillance after…
2021 American Transplant Congress
Urine Donor-derived Cell-free is Valuable for Predicting BK Polyomavirus-associated Nephropathy in Kidney Transplant Recipients
G. Huang¹, X. Chen¹, Y. Huang¹, J. Li¹, R. Deng¹, W. Chen², J. Qiu¹, S. Deng¹, G. Chen¹, Q. Fu¹, C. Wu¹, J. Fei¹, L. Liu¹, L. Chen¹, C. Wang¹
¹Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
*Purpose: Our previous study has proved that urine donor-derived cell-free DNA (dd-cfDNA) can assist in the diagnosis of BK polyomavirus-associated nephropathy (BKPyVAN), but its specificity…
2021 American Transplant Congress
Donor Derived Cell Free Dna: Teasing Out the Optimal Threshold for Antibody Mediated Rejection
M. Mattu¹, H. Murad¹, M. Merzkani¹, A. Malone¹, R. Delos Santos¹, M. Wang², B. Wang², S. Chang², T. Alhamad¹
¹Department of Medicine, Washington University in St Louis, St Louis, MO, ²Washington University in St Louis, St Louis, MO
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) assay is a putative noninvasive marker for renal allograft rejection and other etiologies of injury such as BK nephropathy. The…
2021 American Transplant Congress
Liver Transplantation Following Checkpoint Inhibitor Therapy – Timing is Everything
G. T. Schnickel¹, J. Parekh¹, Y. Kono², J. Berumen¹, V. Ajmeera², K. Mekeel¹
¹Division of Transplant and Hepatobiliary Surgery, Department of Surgery, University of California San Diego, San Diego, CA, ²Division of Gastroenterology, Department of Medicine, University of California San Diego, San Diego, CA
*Purpose: Use of checkpoint inhibitors (CPI) prior to liver transplantation has not been well studied and limited case reports describe a risk of early graft…